What separates the life sciences CEOs who build enduring companies from those who don't? In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms. Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart. This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions. For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value. "The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom."
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
David H. Crean is the author of Dual Fluency. He is founder and managing partner of Cardiff Advisory, an investment banking M&A firm focused on healthcare and life sciences companies. His career has taken him from scientist to corporate and business development, M&A, investment banking, venture capital and entrepreneurship. Today he advises companies on issues of growth, partnering, and exit while also leading CEO360, a peer-to-peer platform for early stage life sciences companies.His career over 30 years has evolved because he kept learning, built relationships with people who could help him grow, became comfortable moving into unfamiliar territory and eventually began sharing what he learned with others. Those same ideas now show up throughout his work with Cardiff Advisory, CEO360 and Dual Fluency.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Ihre gesetzlichen Garantierechte: Alle Verbraucher:innen in der EU profitieren von mindestens 2 Jahren gesetzlichem Garantieschutz für alle in der EU verkauften Konsumgüter. Mehr erfahren
Anbieter: California Books, Miami, FL, USA
Zustand: New. Artikel-Nr. I-9798952851160
Anzahl: Mehr als 20 verfügbar
Anbieter: Home-set, Mannheim, Deutschland
Gebundene Ausgabe. Zustand: Neu. What separates the life sciences CEOs who build enduring companies from those who don't?In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions.For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value."The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom." Sprache: Englisch Gewicht in Gramm: 412. Artikel-Nr. IB-11502515
Anzahl: 2 verfügbar